Remote Ischemic Preconditioning to Prevent Early Worsening After a Small-Vessel Stroke
Tests remote ischemic preconditioning to prevent early worsening in adults with acute perforating artery stroke.
Plain-language title generated from the registry record
Registry title: Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction
Key facts
- Where
- Nanjing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a recent, small stroke caused by a blocked deep brain artery. It tests whether a cuff on the arm can prevent early worsening.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke starting within the last 48 hours, with mild symptoms (NIHSS score ≤5) and a single small infarct (≤30 mm) in a perforating artery area on DWI scan. The parent artery is narrowed by less than 70%.
- Earlier treatment
- People who already had intravenous thrombolysis or endovascular treatment before joining cannot join.
Main reasons for not taking part
- Treatment with intravenous thrombolysis or endovascular treatment before joining
- History of bleeding inside the skull
- Conditions that make the arm cuff unsafe, such as severe arm injury, fracture, subclavian artery stenosis or peripheral vascular disease
- Uncontrolled severe high blood pressure (systolic ≥180 mmHg or diastolic ≥110 mmHg)
- Severe liver or kidney problems, or pregnancy
Read by machine on 12 November 2026.
Where in China
- Jinling Hospital, Medical School of Nanjing University, NanjingNanjing, ChinaContact: Wusheng Zhu, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Jinling Hospital, China
- Trial code
- NCT07237542
- Record updated
- 3 February 2026
- Original description
This study aims to conduct a prospective, randomized, double-blind, multicenter, parallel-controlled, group-sequential trialto scientifically evaluate the safety and efficacy of remote ischemic preconditioning (RIC) in preventing early neurological deterioration (END) in patients with acute perforating artery infarction (PAI).Read full original descriptionShow less
Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction (RIC-END): A Randomised Multicentre Trial
This study aims to conduct a prospective, randomized, double-blind, multicenter, parallel-controlled, group-sequential trialto scientifically evaluate the safety and efficacy of remote ischemic preconditioning (RIC) in preventing early neurological deterioration (END) in patients with acute perforating artery infarction (PAI).
Inclusion: Age 18 years or older; Diagnosed with acute ischemic stroke; Clinical symptoms consistent with perforating artery infarction (NIHSS score ≤5, with consciousness item 1a ≤1); Time from onset to randomization within 48 hours; Diffusion-weighted imaging (DWI) showing a single infarct in the perforating artery territory with a maximum diameter ≤30 mm, meeting at least one of the following:; (1) Diameter ≤15 mm and involving two or more axial slices; (2) Maximum diameter ≥15 mm; (3) Connected to the ventral surface of the pons but not crossing the midline; 6) Stenosis of parent artery <70%; 7) Signed informed consent obtained from the patient or their legally authorized representative.
Exclusion: Received intravenous thrombolysis or endovascular treatment prior to randomization; Secondary stroke caused by brain tumor, traumatic brain injury, hematologic disorders, or other conditions; History of intracranial hemorrhage; Presence of RIC contraindications, such as severe upper limb soft tissue injury, fracture, subclavian artery stenosis, or peripheral vascular disease; Uncontrolled severe hypertension (systolic blood pressure [BP] ≥180 mmHg or diastolic BP ≥110 mmHg); Patients with thrombocytopenic purpura, coagulation disorders, or active visceral bleeding; Patients in the acute phase of fundus hemorrhage; History of severe aphasia or psychiatric disorders affecting clinical assessment; Severe hepatic or renal dysfunction (Alanine Aminotransferase or Aspartate Aminotransferase > 3 × upper limit of normal; creatine kinase >3 × upper limit of normal; estimated Glomerular Filtration Rate < 30 mL / min / 1.73 m²); Life expectancy <90 days; Pregnancy; Inability to comply with follow-up; Participation in other clinical trials.